title: Intravenous thrombolysis in German stroke units before and after regulatory approval of recombinant tissue plasminogen activator.
abstract: BACKGROUND
  Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) within 3 h after onset of focal cerebral ischemia was approved in Germany in August 2000.
  
  
  METHODS
  11 neurology departments with acute stroke units participated in the German Stroke Study Collaboration before (n = 2,925) and after (n = 3,204) approval of rt-PA in Germany and consecutively registered all patients admitted within 24 h following acute ischemic stroke.
  
  
  RESULTS
  Frequency of intravenous thrombolysis in patients admitted within 24 h after symptom onset increased from 4.8% before approval to 7.9% after approval of rt-PA. Among patients treated with rtPA, age increased significantly and the delay between symptom onset and imaging was significantly shorter in the second study period.
  
  
  CONCLUSIONS
  The observed improvement in management and quantity of intravenous thrombolysis may be explained by greater experience and greater legal security following regulatory approval of rtPA.
authors.affiliation: Department of Neurology, University of Duisburg-Essen, Essen, Germany. stroke.med@uni-essen.de
authors.forename: C
authors.initials: C
authors.lastname: Weimar
authors.forename: K
authors.initials: K
authors.lastname: Kraywinkel
authors.forename: M
authors.initials: M
authors.lastname: Maschke
authors.forename: H-C
authors.initials: HC
authors.lastname: Diener
mesh_terms: D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000375:Aging; D017277:Drug Approval; D004363:Drug Utilization; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005858:Germany; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator